ALLR Stock Overview A clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Allarity Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Allarity Therapeutics Historical stock prices Current Share Price US$1.02 52 Week High US$327.18 52 Week Low US$0.90 Beta 0.20 1 Month Change -7.27% 3 Month Change -36.25% 1 Year Change -99.66% 3 Year Change -100.00% 5 Year Change n/a Change since IPO -100.00%
Recent News & Updates
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement Oct 12
Allarity Therapeutics, Inc. Announces Management Appointments Oct 03 Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc
Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer Sep 13
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) Sep 12
Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance Jun 29 See more updates
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement Oct 12
Allarity Therapeutics, Inc. Announces Management Appointments Oct 03 Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc
Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer Sep 13
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) Sep 12
Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance Jun 29
Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer Jun 26 Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial May 26 Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million. May 09
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib May 03
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement Apr 30
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) Apr 17
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer Mar 28
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) Mar 26 Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million. Mar 20
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding Mar 16
Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP Feb 15
Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board Feb 02 Allarity Therapeutics Announces Executive Changes
Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic Dec 05
Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff Nov 18
Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2) Oct 31
Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology Sep 15
Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE Sep 01
Allarity Therapeutics, Inc. Announces Board Changes Aug 12
Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics Aug 02
Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update Jul 29
Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives Jul 25
Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients Jul 06 Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP
Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price Jun 30
Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study May 31
Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market May 29
Allarity Therapeutics, Inc. Announces Board Changes Jan 22
Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares Dec 23
High number of new and inexperienced directors Nov 16
Allarity Therapeutics Receives Notice from the Nasdaq Oct 17
Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements Oct 12
Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46 Oct 11
Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022 Sep 27
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Aug 27
Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07 Aug 23
Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022 Aug 17
Allarity Therapeutics, Inc. announced delayed 10-Q filing Aug 16
Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors Jul 12 Allarity Therapeutics, Inc. Announces Executive Leadership Transition
Allarity Therapeutics appoints interim CEO, CFO Jun 29
Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board Jun 16
Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022 May 29 Allarity Therapeutics, Inc. announced delayed 10-Q filing May 18
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Apr 23 Allarity Therapeutics, Inc. announced delayed annual 10-K filing Apr 03
Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA Feb 19
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC) Dec 23 Shareholder Returns ALLR US Biotechs US Market 7D -8.9% 0.2% -0.2% 1Y -99.7% -4.7% 25.8%
See full shareholder returns
Return vs Industry: ALLR underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: ALLR underperformed the US Market which returned 25.8% over the past year.
Price Volatility Is ALLR's price volatile compared to industry and market? ALLR volatility ALLR Average Weekly Movement 11.4% Biotechs Industry Average Movement 11.0% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ALLR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALLR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty.
Show more Allarity Therapeutics, Inc. Fundamentals Summary How do Allarity Therapeutics's earnings and revenue compare to its market cap? ALLR fundamental statistics Market cap US$4.70m Earnings (TTM ) -US$19.42m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALLR income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$19.42m Earnings -US$19.42m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.38 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 10.3%
How did ALLR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 01:29 End of Day Share Price 2025/01/06 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Allarity Therapeutics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Nathaniel Calloway Edison Investment Research Aydin Huseynov Ladenburg Thalmann & Company
Show 0 more analysts 